[go: up one dir, main page]

WO2004039968A1 - Lignee de cellules dendritiques immortalisees provenant de la moelle osseuse - Google Patents

Lignee de cellules dendritiques immortalisees provenant de la moelle osseuse Download PDF

Info

Publication number
WO2004039968A1
WO2004039968A1 PCT/JP2003/013951 JP0313951W WO2004039968A1 WO 2004039968 A1 WO2004039968 A1 WO 2004039968A1 JP 0313951 W JP0313951 W JP 0313951W WO 2004039968 A1 WO2004039968 A1 WO 2004039968A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell line
cells
dendritic cell
immortalized
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2003/013951
Other languages
English (en)
Japanese (ja)
Inventor
Toshiyuki Takai
Masuo Oginata
Yumi Ito
Kozue Ito
Shin Ebihara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
Original Assignee
Japan Science and Technology Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science and Technology Agency filed Critical Japan Science and Technology Agency
Publication of WO2004039968A1 publication Critical patent/WO2004039968A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Definitions

  • the present invention relates to an immortalized dendritic cell line derived from bone marrow. More specifically, the present invention relates to a transgenic mouse transfected with the large T antigen gene of a temperature-sensitive mutant tsA58 of SV40 (tMs s SV40). Dendritic cells (DCs) derived from the bone marrow of LTT g mice)
  • the present invention relates to an immortalized dendritic cell line that can be established, a method for producing the cell line, and use thereof.
  • the immortalized dendritic cell line of the present invention can be applied to in vitro analysis of dendritic cells, development of vaccine therapy using dendritic cells, and study of modification and enhancement of immune response. Background art
  • immortalized cells that have acquired the ability to proliferate indefinitely while avoiding cell senescence during repeated passage of primary culture will have stable and uniform characteristics. Many cells lose some or all of the morphology and functions that cells originally have in living organisms. Therefore, it has been considered difficult to accurately reflect the original characteristics of the tissue from which the cell line is derived in a test using such an immortalized cell line.
  • oncogenes such as the ras gene and the c-myc gene, the adenovirus ElA gene, the SV40 virus large T antigen gene, and the human papillomavirus HPV16 gene were introduced into primary cells.
  • Dendritic cells are dendritic cell populations derived from hematopoietic stem cells and are widely distributed in vivo. Immature dendritic cells recognize and take in foreign substances, such as viruses and bacteria, that have invaded their tissues, and generate peptides by digestion and degradation in the process of migrating to lymphoid organ T cells. By binding to MHC molecules and presenting them on the cell surface, they act as antigen-presenting cells that activate antigen-specific T cells and induce an immune response (Ann. Rev. Immunol. 9, 271-296, 1991, J.
  • DCs are very important for the initiation of T cell responses that can elicit T cell-dependent early immune responses.
  • the immature DCs take up the antigen, mature and migrate to secondary lymphoid organs. It accumulates in the T cell area and selectively activates antigen-specific T cells circulating in the body to drive an immune response.
  • these detailed mechanisms in DC in vivo are still unknown and need to be analyzed in vitro.
  • GM-CSF granulocyte-macophage phage colony-stimulating factor
  • Dendritic cells are important cells that drive the immune response.
  • DCs can be cultured by preparing them from living organisms, but their lifespan is limited.Even if they are cultured in the presence of cytokines such as GM-CSF, they can survive for as long as about one month and then die. I do.
  • cytokines such as GM-CSF
  • an object of the present invention is to provide an immortalized dendritic cell line that retains the functions and characteristics inherent to dendritic cells, a method for establishing the same, a method for screening a useful substance using the immortalized dendritic cell line, and a method for screening the same.
  • An object of the present invention is to provide a cell vaccine containing an immortalized dendritic cell line as a main component.
  • the present inventors have conducted intensive studies to solve the above problems, and after hemolyzing bone marrow cells of ts SV40 LTT g mice, removing lymphocytes and Ia-positive cells, and obtaining the obtained cells.
  • Dendritic cells are induced by culturing in the presence of GM-CSF, and subculture is repeated 10 times or more.
  • the established immortalized dendritic cell line expresses myeloid and leucosite molecules on the cell surface.
  • the present inventors have confirmed that DCs have inherent properties such as an ability to take up an antigen, an ability to present an antigen, and an ability to induce CTL activity, thereby completing the present invention. Disclosure of the invention
  • the present invention provides an immortalized dendritic cell characterized by being derived from bone marrow.
  • the strain (Claim 1) which expresses a myeloid molecule and a leucosite molecule on the cell surface, and has an antigen uptake ability, an antigen presentation ability, and an ability to induce CTL activity.
  • the immortalized cell line according to claim 1 or 2 A dendritic cell line (Claim 3), an immortalized dendritic cell line according to any one of claims 1 to 3, which has an ability to respond to LPS stimulation (Claim 4), and a rodent
  • the immortalized dendritic cell line according to any one of claims 1 to 4 which is characterized in that it is an origin (claim 5), and the immortalized cell line according to claim 5, wherein the rodent is a mouse.
  • the present invention relates to a dendritic cell line (Claim 6) and an immortalized dendritic cell line TDC (FE RM BP-08527) (Claim 7).
  • the present invention also provides a method for removing lymphocytes and Ia-positive cells after hemolyzing bone marrow cells of a transgenic mouse into which the large T antigen gene of the temperature-sensitive mutant tsA58 of SV40 has been introduced.
  • the obtained cells are cultured in the presence of GM-CSF to induce dendritic cells.Subculture is repeated at least 10 times, expressing myeloid molecules and leucosite molecules on the cell surface, and taking up antigen.
  • a method for producing an immortalized dendritic cell line which comprises establishing a cell line having the ability to present antigen, the ability to present antigen, and the ability to induce CTL activity (claim 8), and growth at 33 ° C.
  • a method for screening a substance that promotes or suppresses maturation of dendritic cells, comprising culturing a denatured dendritic cell line, and measuring and evaluating the expression level of the maturation marker protein in the cell line (claim 10).
  • a method for screening a substance that promotes or suppresses maturation of dendritic cells according to claim 10 (claim 11), and the immortalized tree according to any one of claims 1 to 7, in the presence of a test substance.
  • a method for screening a substance that promotes or suppresses cell growth in dendritic cells (Claim 12), which comprises culturing a dendritic cell line, and measuring and evaluating the degree of proliferation of the cell.
  • an LPS stimulation of the immortalized dendritic cell line according to any one of claims 1 to 7, and measurement and evaluation of the amount of IL-112 produced by the cell, whereby the activation of dendritic cells is promoted.
  • the present invention relates to a method for screening an inhibitor (Claim 13).
  • the present invention further provides a substance for promoting maturation of dendritic cells obtained by the screening method according to claim 10 or 11 (claim 14), and the screening method according to claim 12.
  • a cell growth promoting substance in dendritic cells (Claim 15), a dendritic cell activation promoting substance obtained by the screening method according to Claim 13 (Claim 16), and Claims 1 to 7
  • the immortalized dendritic cell line according to claim 17, wherein the cell vaccine is an immortalized dendritic cell line in which proliferation is suppressed in 37, and the immortalized dendritic cell line is an antigen.
  • FIG. 1 is a photograph showing the results of Wit-Giemsa staining of dendritic cells of the immortalized dendritic cell line of the present invention and dendritic cells of B6 mouse.
  • FIG. 2 shows the MTT assay for the immortalized dendritic cell line of the present invention.
  • FIG. 4 is a view showing the results of measuring the proliferation ability while changing the temperature conditions according to the present invention.
  • FIG. 3 is a view showing the results of measuring the requirement of GM-CSF by MTT assay in the growth of the immortalized dendritic cell line of the present invention.
  • FIG. 4 is a diagram showing the results of analysis of the expression levels of representative myeloid molecules on the immortalized dendritic cell line of the present invention and dendritic cells of B6 mice by FACS.
  • FIG. 5 is a diagram showing the results of analysis of the expression levels of representative leucocyte molecules on the dendritic cell surface of the immortalized dendritic cell line of the present invention and the B6 mouse by FACS.
  • FIG. 6 shows the results of FACS analysis of the antigen uptake ability of the immortalized dendritic cell line of the present invention and the dendritic cells of B6 mice.
  • FIG. 7 is a graph showing the results of FACS analysis of dendritic cell maturity in response to LPS stimulation of immortalized dendritic cell lines of the present invention and dendritic cells of B6 mice.
  • FIG. 8 shows the results of measuring the amount of IL-12p70 produced by dendritic cells of the immortalized dendritic cell line of the present invention and the dendritic cells of B6 mice in response to LPS stimulation by ELISA.
  • FIG. 9 is a diagram showing the results of FVAS analysis of the maturity 2 days after OVA was incorporated into the immortalized dendritic cell line of the present invention and the dendritic cells of B6 mice.
  • FIG. 10 shows the results of the ability of the immortalized dendritic cell line of the present invention and dendritic cells of B6 mice to present antigen to OVA-T cells.
  • FIG. 11 is a diagram showing the time-course anti-OVA antibody titer of OVA transferred to the immortalized dendritic cell line of the present invention and the dendritic cells of B6 mice.
  • FIG. 12 shows the results of immunohistochemical staining (anti-GL-7 antibody) of the spleen germinal center approximately three weeks after the transfer of the dendritic cells of the dendritic cell line of the present invention. It is a photograph.
  • FIG. 13 is a diagram showing the results of comparative examination of the in vivo CTL activity by transferring the dendritic cells of the dendritic cell line of the present invention.
  • FIG. 14 is a diagram showing the results of comparing the expression levels of MHC class I / OVA peptide complexes in the immortalized dendritic cell line of the present invention and dendritic cells of B6 mice.
  • FIG. 15 is a view showing the results of enhanced antitumor activity in vivo by transferring the immortalized dendritic cell line of the present invention.
  • the immortalized dendritic cell line of the present invention may be any immortalized dendritic cell line derived from bone marrow, and can be grown at 33 ° C, and can grow at 37 ° C.
  • a cell line to be suppressed is preferable, and a cell line having characteristics inherent to DC is more preferable except for this temperature sensitivity.
  • cell lines that express myeloid and leucosite molecules on the cell surface and have antigen uptake, antigen presentation, and CTL activity induction, or dendritic cells mature by stimulation with LPS Suitable examples include a cell line that is activated and has the ability to respond to LPS stimulation, such as producing IL-112, and a cell line having these properties in combination.
  • an immortalized dendritic cell line is the immortalized dendritic cell line TDC.
  • This TDC line is deposited at the National Institute of Advanced Industrial Science and Technology, Patent Organism Depositary under the depository number.
  • FE RM BP—085-27 (transferred from FE RM P—19044 deposited on September 26, 2002) has been deposited under the Budapest Treaty.
  • the origin of the immortalized dendritic cell line of the present invention is not particularly limited, but the immortalized dendritic cell line obtained from an animal such as a rodent such as a mouse has an abundant disease model in a mouse, Pharmacological review It is preferred because it is widely used for its value.
  • a method for producing the immortalized dendritic cell line of the present invention will be described by taking a mouse method as an example.
  • the immortalized dendritic cell line of the present invention derived from a mouse can be obtained, for example, by subjecting bone marrow cells of a ts SV40 LTT g mouse to hemolysis using ammonium chloride, for example, an anti-CD4 antibody, an anti-CD8 antibody, an anti-I one a b antibody, anti-rat I g using antibody and Usagi complement, complete R PM I medium cells depleted lymphocytes and I a-positive cells containing the mouse recombinant GM- CSF of 2 0 ng / mL (5% FCS) to induce dendritic cells (DC), repeat subculture 10 times or more, express myeloid molecules and leucosite molecules on the cell surface, It can be obtained by establishing a cell line having the ability to present antigen and the ability to induce CTL activity.
  • ammonium chloride for example, an anti-CD4 antibody, an anti-CD8 antibody, an anti-I one a b antibody, anti-rat I g using antibody and Us
  • the ts SV 40 LTT g mouse can be produced as follows. Plasmid p SV in which ts A58 ori (I) deleted the SV40 replication origin (ori) and opened into pBR322 by opening all 12 DNAs with the restriction oxygen BamHI ts A58 (-) — 2 (O noT. et al., Cytotechnology 7, 165-172, 1991) was amplified in large amounts in E. coli according to a conventional method, and the amplified plasmid was digested with the restriction enzyme BamHI. To remove a portion of the vector to prepare a DNA fragment having the large T ⁇ protogene of tsA58.
  • the DNA fragment containing the promoter of the large T antigen gene was transfected into mouse totipotent cells according to a conventional method, whereby the large T antigen gene of the temperature-sensitive mutant tsA58 of SV40 was transferred to all cells.
  • a transgenic mouse ie, a transgenic mouse, can be produced.
  • the tsA58 large T antigen gene is expressed in all its somatic cells.
  • Specific examples of the totipotent cells include fertilized eggs and early embryos, as well as ES cells having pluripotency. '' And all
  • known gene transfer methods such as a microinjection method, an electric pulse method, a ribosome method, and a calcium phosphate method can be used.
  • the nuclei of the totipotent cells (cultured cells) of the above mice are transplanted into non-fertilized enucleated eggs and initialized (nuclear transfer).
  • An antigen gene can be introduced.
  • the eggs obtained by microinjecting the large T antigen gene of tsA58, a temperature-sensitive mutant of SV40, into the male pronucleus of fertilized eggs at the pronuclear stage were transplanted into the oviduct of the foster mother. After obtaining the offspring, the offspring having the injected gene are selected, and an individual having the gene integrated stably is obtained.
  • transgenic mice ie, transgenic mice, that have been integrated into the chromosomes of these cells can be efficiently produced.
  • the immortalized dendritic cell line of the present invention retains a permanent growth ability at 33 ° C, suppresses growth at 37 ° C, and stops growth at 39 ° C. It has the characteristic of being able to control the expression of the differentiation traits of the plant. In addition, this immortalized dendritic cell line shows good proliferation at 33 ° C. even after being subcultured for 7 months or more, and retains its function as a dendritic cell.
  • the immortalized dendritic cell line of the present invention can continue to proliferate stably, and can activate T cells due to the antigen uptake ability and antigen presentation ability of the dendritic cells. In addition to being useful as a vaccine, it can be used to study the induction and modification of immunity and therapy using dendritic cells. Further, as shown below, it can be used for screening useful substances for dendritic cells.
  • the above-described immortalized dendritic cell line of the present invention is cultured in the presence of a test substance;
  • the present invention also includes a substance for promoting maturation in dendritic cells, a substance for promoting cell growth in dendritic cells, and a substance for promoting activation of dendritic cells, which are obtained by the above-described screening method.
  • the screening of substances for promoting or inhibiting maturation in dendritic cells is performed by culturing immortalized dendritic cell lines in the presence of various concentrations of a test substance, and measuring the amount of marker protein expressed after culturing for a certain period of time. It is performed by detecting and measuring, and comparing and evaluating with a control cultured in the absence of the test substance.
  • myeloid molecules and leucosite molecules which are maturity marker proteins expressed on the surface of dendritic cells, can be measured by immunochemical detection using a specific antibody in a conventional manner. In addition, it can also be measured by detecting the expression level of mRNA corresponding to these by a conventional method.
  • the screening for substances that promote or suppress cell growth in dendritic cells is performed by culturing immortalized dendritic cell lines in the presence of various concentrations of test substances, and measuring the number of cells and cell morphology after culturing for a certain period of time. ⁇ Analyzed and compared with that of a control cultured in the absence of the test substance. Screening for dendritic cell activation-promoting or -suppressing substances is performed by culturing immortalized dendritic cell lines in the presence of various concentrations of test substances, and culturing for a certain period of time. Is measured and compared with that of a control cultured in the absence of the test substance.
  • the cell vaccine of the present invention is not particularly limited as long as it comprises the above-mentioned immortalized dendritic cell line of the present invention as a main component.
  • a dendritic cell line is preferable, and such a human-derived immortalized dendritic cell line is obtained by isolating a dendritic cell line from human peripheral blood or bone marrow, and obtaining a large T of a temperature-sensitive mutant tsA58 of SV40.
  • the large T antigen gene of the temperature-sensitive mutant tsA58 of SV40 was introduced into the human embryonic stem cells (ES cells) by introducing the antigen gene and repeating subculture, or The cells can be differentiated into dendritic cell strains and established by repeating subculture.
  • immortalized dendritic cell lines can grow at 33 ° C, but growth is suppressed at 37 ° C, or immortalized dendritic cell lines Or an antigen-IgG immune complex is preferred.
  • the cellular vaccine of the present invention can be used as an antigen-presenting cell that stimulates T cells, which takes up an antigen in vivo or in vitro and presents an antigenic peptide on the cell surface after modification.
  • a cell vaccine of the present invention comprising a suspension of the immortalized dendritic cell line of the present invention is to be inoculated as a therapeutic vaccine into the human body, but growth is suppressed in 37. Therefore, safety is high.
  • the immortalized dendritic cell line of the present invention requires such cell inactivation treatment. It is unnecessary and can be grown at 33 ° C, but it can be said that it is an extremely safe vaccine because growth is suppressed at 37.
  • the cell vaccine of the present invention in particular, a cell vaccine mainly comprising a human-derived immortalized dendritic cell line, is a cell vaccine that can be transferred to humans, and is used for various tumors such as leukemia, liver cancer, lung cancer, gastric cancer, and colon cancer, and It can be advantageously used for infectious diseases caused by various viruses and bacteria.
  • Cell of the present invention The dose of Kuching varies depending on the patient's age, weight, gender, type of cancer, degree of progression of the cancer, symptoms, etc., and cannot be determined unconditionally. A small amount can be administered to the patient.
  • the cell vaccine of the present invention can be used for patients themselves, but can be administered to a large number of MHC-compatible patients of the same type due to the development of bone marrow banks and cord blood banks.
  • the present invention will be described more specifically with reference to examples, but the technical scope of the present invention is not limited to these examples.
  • Example 1 Production of transgenic mouse
  • mice transfected with the DNA of the temperature sensitive mutant tsA58 of SV40 were created by the following procedure.
  • a genomic DNA of SV40 temperature-sensitive mutant tsA58 modified by genetic engineering was used.
  • the genomic DNA of tsA58 was opened with the restriction enzyme BamHI, introduced into the BamHI site of pBR322, and the S ⁇ iI sequence was converted to SacII to convert SV40 to A DNA clone with an origin of replication (ori) deleted, ori (-) p SV ts A58 ori (-)-2 (Ohno T. et al., Cytotechnolgy, 165-172, 1991)
  • the DNA for introduction was prepared according to the procedure described above.
  • This DNA solution was diluted with a buffer for injection (10 mM Tris-HCl containing 0.1 mM EDTA; pH 7.6) to a concentration of 5 g / m 1 and diluted with DNA for injection. A solution was prepared. The prepared DNA solution was stored at -20 until injection.
  • a buffer for injection 10 mM Tris-HCl containing 0.1 mM EDTA; pH 7.6
  • Microinjection of the above prepared DNA solution for injection into mouse pronucleus fertilized eggs was performed as follows. Sex-matured 8-week-old Wistar mice are bred under a light-dark cycle of 12 hours (4: 00 to 16: 00 light hours), temperature of 23 ⁇ 2 C, humidity of 55 ⁇ 5%, and vaginal smear. The female estrous cycle was observed by, and the date of hormone treatment was selected. First, 150 IU Zkg of pregnant serum serum gonadotropin (PMS gonadotropin (PMS G), manufactured by Nippon Zenjak) was intraperitoneally administered to female mice for 48 hours.
  • PMS gonadotropin PMS gonadotropin
  • human chorionic gonadotropin manufactured by Sankyo Organ Co., Ltd .; human chorionic gonadotropin: hCG
  • hCG human chorionic gonadotropin
  • Pronuclear stage fertilized eggs were collected by tubal perfusion 32 hours after hCG administration.
  • mK RB solution Toyoda Y. and Chang M., J. Reprod. Fertil., 36, 9-22, 1974
  • the collected fertilized eggs were enzymatically treated at 37 ° C for 5 minutes in mKRB solution containing 0.1% hyaluronidase (Sigma; Hyaluronidase Typel-S) to remove cumulus cells. and washed 3 times with a liquid to remove the enzyme, to DNA injection operation C 0 2 - and stored in - (95% of a ir, 3 7 ° C, saturated humidity 5% C_ ⁇ 2) incubator.
  • the DNA solution was injected into the male pronucleus of the mouse fertilized eggs prepared in this manner. Transplanted 2 2 8 eggs into 9 foster parents And gave birth to obtain 80 offspring.
  • the injected DNA was introduced into mice by PCR using DNA prepared from tails obtained by cutting the tails immediately after weaning.
  • mice Male lines: # 07-2, # 07-7-5, # 09-19-6, # 12-23, # 19-19, female lines: # 09-9-7, # 11) 1, # 1 2—5, # 1 2—7, # 1 8—5, # 1 9—8).
  • G. Generation transgenic mice and Wistar mice were bred, and two lines (# 07-7-2, # 07-7-5) of male huaunda and three lines of female founder (# 09-9-7, # 11-16) , # 1918), confirmed the gene transfer to the next generation and beyond.
  • Example 2 Separation and preparation of DC from mouse bone marrow
  • mice Two strains of mice were used, C57BL / 6 (B6 mouse) and temperature-sensitive SV40T antigen transgenic mouse (ts SV40 LTT g mouse; B6 background). All the mice were 6-8 week old females.
  • Mouse bone marrow cells Te to 0. 1 44 M chloride
  • Anmoniumu to erythrocyte lysis treatment, anti-CD 4 antibodies, anti-CD 8 antibodies, anti-I one A b antibody, anti-rat I g antibody (respectively TIB 2 0 7, 2 Lymphocytes and Ia-positive cells were removed using 11, 15 4 and 2 16: Amerikan Type Culture Collection) and Egret complement (Cedarlane).
  • DC dendritic cells
  • Example 2 The DC obtained in Example 2 was stained with Wright-Giemsa. DCs originating from two strains, B6 mouse and ts SV40 LTT g mouse, were adhered to slide glass by site spin, and the light Giemsa method (light stain and Giemsa stain, both manufactured by Merck) ) And visualized. The results are shown in Figure 1. As a result, the cell size of tsSV40LTTg DC (SV40TB6) was larger than that of B6 mouse DC (primary culture B6). Example 4 (Proliferation ability at different temperatures)
  • MTT (3- (4,5-dimethyltiazol-2-yl) -2,5-diphenyltetrazo-1ium bromide) is cleaved by the dehydrogenase of the inner mitochondrial membrane and has a purple-red MT. Generate T-iormazan. Based on the fact that this color reaction is proportional to the proliferative capacity of the cells, the MTT assay at ts SV40 LTT g at different temperatures (33 ° C, 37 ° C, 39 ° C) was measured for its proliferation ability.
  • MTT Atsushi was prepared by adding 10 L of a 5 mg / mL MTT (Sigma) solution to the above-mentioned 2 ng / mL mouse recombinant GM—CSF (Peprotech
  • MTT assay was performed under the same conditions as in Example 4. That is, 10 L of a 5 mg / mL MTT (Sigma) solution was added to a cell suspension containing mouse recombinant GM-CSF (Peprotech) at concentrations of 20, 10, 2, and OngZmL, respectively. was added to 0 t L, 9 to 6 well plates 7. plated cells at 5 X 1 0 3/1 0 0 n L / well, MT T solution was added 1 0 x L / well at the time of measurement, over time A measurement was made. The results are shown in Figure 3.
  • MTT granulocyte macrophage colony stimulating factor
  • the immortalized cells were found to be cells that proliferate in a GM-CSF-dependent manner.
  • Example 6 (Examination of proteins expressed on the cell surface)
  • ts SV 40 LT T g mice (SV 40 TB 6) and B 6 mice (primary culture B 6) were used as DCs, and 10 / g / mL antigen (OVA-FI On the second day after addition of TC (Molecule Probes), the uptake capacity was compared by FACS. Fig. 6 shows the results. As a result, DC of tsSV40LTTg showed stronger uptake ability than DC of B6 mouse.
  • Example 8 Comparative study of maturation of dendritic cells to LPS stimulation
  • ts SV 40 LTT g mouse S V40 TB 6
  • B 6 mouse primary culture B 6
  • p70 production was measured by ELISA.
  • Fig. 8 shows the results. As a result, 2 g / mL of LPS was added to each DC culture well, and 24 hours later, the amount of IL-12p70 produced in the supernatant did not change between the two strains.
  • ts SV 40 LT T g mice (SV 40 TB 6) and B 6 mice (primary culture B 6) originated from 10 strains of DCs, respectively. After incorporation, their maturity was analyzed by FACS two days later. The results are shown in FIG. As a result, DC of B6 mouse (primary culture 6) showed stronger maturity.
  • Example 11 1 Comparative study of the ability of dendritic cells to present antigen to OVA-T cells
  • ts SV40 LTT g mice SV The antigen presenting ability of each DC derived from two strains, 40 TB 6) and B 6 mouse (primary culture B 6) was measured.
  • the IL-14 production and proliferation of T cells were measured as presentation ability.
  • X-ray irradiated DC 5 X 1 0 3 / well
  • OVA or OVA-I g G immune complexes (IC) 9 6-well in the presence Co-culture was performed on the plate. It is said that highly efficient antigen presentation occurs when an immune complex incorporates an antigen through the Fc ⁇ receptor (J. Immunol., 161, 6059-6067, 1998, J. Exp. Med. , 189, 371-380, 1999, Eur. J. Immunol., 30, 848-857, 2000, J. Exp. Med., 195, F1-F3, '2002).
  • the OVA-IgG immune complex was prepared by mixing ovalbumin (OVA; Sigma) with Egret Anti-OVAI gG (BioDesign) in a weight ratio of 1:10, It was prepared for one hour with a computer. Twenty-four hours later, the culture supernatant was collected, and the amount of IL-14 produced by the T cells was measured by ELISA. T cell proliferation was determined by measuring [ 3 H] —T dR incorporation after 48 hours of co-culture. The results are shown in FIG. As a result, each of the DCs originating from the two lines both had the same leprosy T cell proliferation and IL-14 production.
  • mice SV 40 TB 6 and B6 mice (primary culture B 6) were loaded with OVA or OVA A-IgG immune complex on each DC. Then, the anti-OVA antibody titer over time after the transfer was examined.
  • mature DCs with antigen were recovered two days after replacement of the culture medium with fresh medium containing OVA or OVA_IgG immune complex at 10 ⁇ g / mL.
  • PBS (-) was washed with and populate the recipient to become B 6 mice DC 1 X 1 0 6 cells per animal into the tail vein. After immunization, blood was collected from the fundus, and the anti-OVA antibody titer over time was measured by ELISA.
  • mice The in vivo CTL activity by DC transfer into mice was compared. Spleen cells of mice after transfection 7 days were taken to remove the adherent cells by incubating for 30 minutes at C_ ⁇ 2 incubator 3 7 ° C, and the T cell-rich. This nonadherent cells 1 X 1 0 7, E. G 7 stopping the X-ray irradiation proliferate - the OVA 1 X 1 0 6 were co-cultured in 24-well plates.
  • E. G 7 -0 VA (CRL2113; ATCC) is a transfection of OVA cDNA into EL-14, a thymoma derived from B6, and the OVA peptide is always loaded on its MHC class I. Have been.
  • Example 14 when OVA was added to DC of ts SV 40 LTT g, compared to DC of B6 mouse (primary culture B6), it was almost the same as when the immune complex was incorporated.
  • the reason for the induction of the rather strong CTL activity was that more antigen-derived peptides were presented on the DC MHC class I molecule, and the specificity of the MHC class I / OVA peptide complex Site using typical monoclonal antibodies
  • FIG. 14 shows the result of histogram showing the amount of MHC I or MHC I / ⁇ VA peptide cell surface expression of dendritic cells (CD1lc positive cells).
  • Ts SV40 LTT g mice SV40T ⁇ 6 mice and ⁇ 6 mice (primary culture ⁇ 6), which were given OVA stimulation (10 g / m 1, 48 hours)
  • Each DC (5 ⁇ 10 5 / mouse) or saline (200 1) was administered through the tail vein of naive mice (7 to 8), and after 7 days, DC or After administration of saline, tumor cells expressing OVA (E. G 7) planting in 1 X 1 0 5 Nomausu the left thigh, the day tumor formation was additionally connexion observed, those tumor diameter of more than 5 mm is determined that the tumor is formed.
  • the tumor suppression rate in FIG. 15 is the percentage of mice in which no tumor was formed, expressed as a percentage. Mice to which ts SV40 LTT g DC had been transferred had slower tumor formation than mice to which wild-type B6 mouse DC had been transferred, and efficiently suppressed tumor formation. That is, it was found that ts SV40 LTT g DCs are cells that induce antitumor activity more efficiently in vivo than wild-type DCs. (Discussion)
  • DCs derived from bone marrow cells of ts SV 40 LTT g mice, passaged at least 10 times, and subjected to long-term culture for at least 7 months at 33 were slightly larger in size than those in the initial culture, and Although the ability was high, it was found that the ability to present Bobara in the mouth of the mouth had the same function as that via MHC class II. From this, it is considered that the cell line is useful for use in the analysis of DC in vitro. In addition, when used as a vaccine in vivo, it induced CTLs particularly strongly via MHC class I. This is consistent with the report that high-efficiency MHC class I-mediated presentation depends on high antigen uptake (Annu. Rev. Immunol., 19, 47-64, 2001). From this, DC of tsSV40LTTg can efficiently induce a vaccine effect against cancers and viruses in vivo.
  • the dendritic cell line can be used for induction and modification of immunity, development of a therapeutic method using the dendritic cell line, and the like. Further, according to the present invention, a method for screening a useful substance against dendritic cells and a substance that enhances an immune response using the cell line are provided, since the cell line retains its original function and characteristics in a tissue derived from the cell line. can do.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention porte sur des lignées de cellules dendritiques immortalisées ayant les fonctions et propriétés inhérentes aux cellules dendritiques, sur leur méthode d'obtention, sur une méthode de criblage d'une substance utile au moyen desdites lignées et sur un moyen à base de cellules dont lesdites lignées sont le constituant principal. L'élaboration d'une lignée de cellules dendritiques immortalisées capable d'absorber un antigène, de présenter un antigène et d'introduire une activité de CTL comporte les étapes suivantes: hémolyse de cellules de moelle osseuse de souris transgéniques porteuse d'un gros antigène T de souche thermosensible tsA58 de mutant SV40 y ayant été transférée; extraction des cellules hémolysées, des lymphocytes et des cellules Ia positives; culture des cellules ainsi obtenues en présence de GM-CSF pour produire les cellules dendritiques; et sous-cultures répétées des cellules, 10 fois ou plus. On obtient ainsi l'expression de molécules myéloïdes et de leucocytes à la surface des cellules.
PCT/JP2003/013951 2002-10-30 2003-10-30 Lignee de cellules dendritiques immortalisees provenant de la moelle osseuse Ceased WO2004039968A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002316871 2002-10-30
JP2002-316871 2002-10-30

Publications (1)

Publication Number Publication Date
WO2004039968A1 true WO2004039968A1 (fr) 2004-05-13

Family

ID=32211699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/013951 Ceased WO2004039968A1 (fr) 2002-10-30 2003-10-30 Lignee de cellules dendritiques immortalisees provenant de la moelle osseuse

Country Status (1)

Country Link
WO (1) WO2004039968A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292267B1 (fr) * 2004-05-31 2014-07-23 Almirall S.A. Combinaisons comportant des agents anti-muscariniques et agonistes béta-adrénergiques
EP3350318A4 (fr) * 2015-09-15 2019-11-13 NorthWest Biotherapeutics, Inc. Procédés relatifs à des compositions de cellules dendritiques activées et traitements immunothérapeutiques pour des sujets atteints de cancers avancés

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
INABA, K. ET AL: "Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor", J.EXP.MED, vol. 176, 1992, pages 1693 - 1702, XP000386312 *
LUTZ, M.B. ET AL: "Retroviral immortalization of phagocytic and dendritic cell clones as a tool to investigate functionnal heterogeneity", J.IMMUNOL.METHODS, vol. 174, no. 1-2, 1994, pages 269 - 279, XP002986709 *
MASUO TATEWAKI: "transgenic Mouse o Mochiita Bunka Kino Hoji Saibokabu no Juritsu", SEIKAGAKU, vol. 67, no. 12, 1995, pages 1391 - 1396, XP002986706 *
MASUO TATEWAKI: "Zoketsu Kansaibo no Zoshoku to Bunka no Kotsuzui- Kanshitsu Saibo ni yoru Seigyo", JAPANESE JOURNAL OF TRANSFUSION MEDICINE, vol. 44, no. 3, 1998, pages 418 - 420, XP002986707 *
NOBLE, M. ET AL: "the H-2KbtsA58 transgenic mouse: a new tool for the rapid generation of novel cell lines", TRANSGENIC RES, vol. 4, no. 4, 1995, pages 215 - 225, XP001005996 *
SCHEICHER, C. ET AL: "Dendritic cells from mouse bone marrow: in vitro differentiation using low doses of recombinant granulocyte-macrophage colony-stimulating factor", J.IMMUNOL.METHODS, vol. 154, no. 2, 1992, pages 253 - 264, XP002986708 *
VOLKMANN, A. ET AL: "A conditionally immortalized dendritic cell line which differentiates in contact with T cells or T cell-derived cytokines", EUR.J.IMMUNOL, vol. 26, no. 11, 1996, pages 2565 - 2572, XP008022329 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292267B1 (fr) * 2004-05-31 2014-07-23 Almirall S.A. Combinaisons comportant des agents anti-muscariniques et agonistes béta-adrénergiques
EP3350318A4 (fr) * 2015-09-15 2019-11-13 NorthWest Biotherapeutics, Inc. Procédés relatifs à des compositions de cellules dendritiques activées et traitements immunothérapeutiques pour des sujets atteints de cancers avancés
EP3971285A3 (fr) * 2015-09-15 2022-06-22 NorthWest Biotherapeutics, Inc. Compositions de cellules dendritiques activées et traitements immunothérapeutiques pour des sujets atteints de cancers avancés

Similar Documents

Publication Publication Date Title
EP0866655B1 (fr) Modele murin pour la croissance du carcinome humain
Schaefer et al. Observation of antigen-dependent CD8+ T-cell/dendritic cell interactions in vivo
CN113930446B (zh) 对非人动物基因改造的方法及构建的免疫缺陷动物模型
JP2012531896A (ja) ヒト化非ヒト哺乳動物を製造する方法
KR20100096137A (ko) 미생물 질환의 치료를 위한 조성물 및 방법
CN111485002A (zh) 一种重度免疫缺陷的转基因小鼠的制备方法及其应用
JP4609855B2 (ja) ヒト由来免疫担当細胞の製造方法
JP5542928B2 (ja) ミミズの生殖巣再生能力を利用した形質転換ミミズの作製方法、これにより作製された形質転換ミミズ、及び形質転換ミミズの体液から組換たんぱく質の生産方法
JP2011520473A (ja) 抗腫瘍細胞
CN113355355B (zh) Il23a和/或il12b基因人源化非人动物的构建方法及应用
JP4219789B2 (ja) 骨髄由来の不死化樹状細胞株
WO2004039968A1 (fr) Lignee de cellules dendritiques immortalisees provenant de la moelle osseuse
JP4033390B2 (ja) 不死化ナチュラルキラー細胞株
AU2002362474B2 (en) Nonhuman mammal model of autoimmune disease having OX40L gene transferred thereinto
Joannou et al. γδ thymocyte maturation and emigration in adult mice
CN107920499A (zh) 血液嵌合动物的制作方法
CN101899445A (zh) 一种转导iASPPsv癌基因在造血系统特异性高表达的小鼠模型及其制备方法和用途
US20030044398A1 (en) Methods for producing antibodies in mammals
CN102296072A (zh) 转导iASPP-FL癌基因在造血系统特异性高表达的小鼠模型及其制备方法和用途
CN113564203A (zh) HSV1-tk/GCV诱导型血液系统缺陷小鼠模型的制备方法及应用
CN116284409A (zh) Gpc3 car-t细胞及其在制备治疗癌症的药物中的用途
JP5186637B2 (ja) トランスジェニック非ヒト哺乳動物およびその利用
WO2022050082A1 (fr) AGENT POUR AUGMENTER LA TENEUR EN ANTICORPS IgA DANS LE LAIT
CN113711991A (zh) 一种以pap为靶点的药物筛选动物模型的构建方法和应用
WO2002074938A1 (fr) Procedes de production d'anticorps chez des mammiferes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase